N/A
N=1,349
Efficacy and Tolerability of Xalatan in Patients
Glaucoma · Ocular Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT00950690 ↗Enrolled (actual)
1,349
Serious AEs
—
Results posted
Aug 2009
Primary outcome: Primary: Intraocular Pressure
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Xalatan 0.005% eye drops (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Primary completion
- Dec 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure |
— | — |
| PRIMARY Humphrey Perimetry Visual Field |
— | — |
Summary
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
Eligibility Criteria
Inclusion Criteria
- Patient with ocular hypertension at least 22mg Hg
- Patient must be over 18 years old
Exclusion Criteria
- None listed in the protocol
Data sourced from ClinicalTrials.gov (NCT00950690). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.